[The slow acceptance of new oral anticoagulants in Italy: a critical analysis of a problem]. in Giornale italiano di cardiologia (2006) / G Ital Cardiol (Rome). 2017 Mar;18(3):208-218. doi: 10.1714/2674.27398.
2017
AO Cuneo
Tipo pubblicazione
Review
Autori/Collaboratori (13)Vedi tutti...
Pusineri E
U.O. Cardiologia, Istituto Clinico Sant'Ambrogio, Milano.
Proto C
Cardiologia, Istituto Clinico S. Anna, Brescia.
Visconti LO
S.C. Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
et alii...
Abstract
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical practice has revolutionized the prevention and the therapeutic approaches to thromboembolic events in patients with nonvalvular atrial fibrillation and represents with no doubts one of the most remarkable advances in the history of cardiovascular medicine over the last years. NOACs beyond a comparable efficacy with vitamin K antagonists allow to overcome the limitations of this last category of drugs owing to their less drug to drug interactions and a predictable anticoagulant effect that allows a fixed dose administration without the need for continuous monitoring. However, the penetration of NOACs into the Italian market is still lower than predicted with respect to their use in other European countries.The aim of this review is to critically analyze the reasons behind this attitude through the adoption of the nominal group technique, a methodology that permits to reach an official consensus.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 28398379
DOI : 10.1714/2674.27398
Keywords
Italy; Humans; Time Factors; Thromboembolism/etiology/prevention & control; Drug Utilization; Attitude of Health Personnel; Atrial Fibrillation; Anticoagulants/administration & dosage; Stroke/etiology/prevention & control; Administration, Oral;